Locations
Cambridge, MA, USA · Cambridge, MA, USA
industry
Biotechnology · DeepTech · Health
Size
51-200 employees
Stage
Series C+
founded in
2015
Obsidian Therapeutics is pioneering engineered cell and gene therapies using its proprietary cyto DRi VE® platform to develop precision medicines. The company focuses on creating adoptive immunotherapies, particularly through its lead clinical program OBX-115, which has received FDA designations for advanced melanoma treatment. Their innovative approach allows for controlled protein activity in cells, enhancing the efficacy of cell therapies. With a strong pipeline and collaborations with major partners, Obsidian is positioned to make significant impacts in oncology and improve patient outcomes.
Something looks off?On-site & Remote